Search
beta-Naphthoflavone
go.drugbank.com/drugs/DB06732Experimentalβ-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs).
Deudextromethorphan
go.drugbank.com/drugs/DB19054InvestigationalDeudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an
Altropane I-123
go.drugbank.com/drugs/DB15144InvestigationalAltropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the
gamma-Butyrolactone
go.drugbank.com/drugs/DB04699ExperimentalIllicitIt is also used as a pharmacological agent and solvent.
Sodium tripolyphosphate
go.drugbank.com/drugs/DB11493InvestigationalVet approvedIt is used as a component of a wide range domestic and industrial products, particularly detergents.
MP4
go.drugbank.com/drugs/DB05313InvestigationalMP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.
Cyclohexanone
go.drugbank.com/drugs/DB02060ExperimentalCyclohexanone (also known as oxocyclohexane, pimelic ketone, ketohexamethylene, cyclohexyl ketone or ketocyclohexane) is a six-carbon cyclic molecule with a ketone functional group.
Mirfentanil
go.drugbank.com/drugs/DB09175ExperimentalAt high doses, it exhibits analgesic activity which is not fully reversed by opioid antagonists, suggesting that the drug has both opioid and non-opioid mechanisms of action.
Chlorophyll B
go.drugbank.com/drugs/DB04506ExperimentalIt has the atomic symbol Mg, atomic number 12, and atomic weight 24.31.
Tuparstobart
go.drugbank.com/drugs/DB19118InvestigationalTuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS